To avoid serotonin syndrome in a patient on a Selective Serotonin Reuptake Inhibitor (SSRI), what is recommended? Select one:

Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), are commonly used in adolescents and young adults to treat major depressive disorder and anxiety disorders. While effective in improving mood and function, these medications carry important safety concerns during the early phase of treatment. One of the most significant risks identified in this population is a potential increase in suicidal thoughts and behaviors. This risk is most prominent during initiation or dose changes, requiring close monitoring.

Rationale:
A. Suicidal ideation is the key black box warning associated with antidepressant use in adolescents and young adults, including agents like Selective serotonin reuptake inhibitors (SSRIs). The warning highlights the increased risk of worsening depression or emergence of suicidal thoughts during early treatment. This necessitates careful monitoring, frequent follow-up, and patient and family education about behavioral changes.

B. Growth retardation is not a recognized black box warning for antidepressant medications. While some psychotropic drugs may have indirect effects on appetite or weight, there is no established boxed warning regarding impaired growth in teens taking antidepressants. This option reflects a misunderstanding of antidepressant safety concerns.

C. Agranulocytosis is a severe hematologic adverse effect associated with certain medications such as clozapine, not antidepressants. SSRIs and most antidepressants do not carry a black box warning for bone marrow suppression or severe neutropenia. Therefore, this is not relevant to antidepressant safety in youth.

D. Increased use of recreational drugs is not a documented black box warning for antidepressant therapy. While substance use may co-occur with depression in adolescents, antidepressants themselves are not associated with causing increased recreational drug use. This is not part of FDA-mandated safety warnings for this medication class.

Uncomplicated urinary tract infections (UTIs) are common in healthy adolescent and adult females and are most often caused by Escherichia coli. First-line empiric treatment is selected based on likely organisms, local resistance patterns, patient allergies, and severity of illness. In an afebrile patient without recent antibiotic exposure or complicating factors, short-course oral therapy is usually sufficient. The goal is to effectively eradicate the infection while minimizing resistance and unnecessary broad-spectrum antibiotic use.

Rationale:
A. Nitrofurantoin (Macrobid) is a preferred first-line treatment for uncomplicated lower urinary tract infections. It concentrates well in the urine and is highly effective against common pathogens such as E. coli. It is especially appropriate in healthy, afebrile patients without signs of pyelonephritis because it provides targeted therapy with a lower risk of widespread antibiotic resistance.

B. Amoxicillin/Clavulanate (Augmentin) can be used for UTIs in some cases, but it is not usually the preferred first-line empiric option for uncomplicated cystitis. Resistance among common urinary pathogens is higher compared with nitrofurantoin, and broader-spectrum coverage may be unnecessary. It is more often reserved for cases where first-line agents are contraindicated or culture results indicate susceptibility.

C. Azithromycin (Zithromax) is not appropriate for routine treatment of uncomplicated UTIs because it has poor activity against the most common urinary pathogens, particularly E. coli. It is more commonly used for respiratory infections and certain sexually transmitted infections. Its pharmacologic profile does not make it effective as standard empiric therapy for cystitis.

D. Ciprofloxacin (Cipro) is effective against urinary pathogens but is generally not recommended as a first-line treatment for uncomplicated UTIs in young healthy patients. Fluoroquinolones are reserved for more complicated infections due to concerns about resistance and serious adverse effects such as tendon injury and central nervous system complications. Safer narrow-spectrum options are preferred first.